Equities

Kopran Ltd

KOPRAN:NSI

Kopran Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)323.40
  • Today's Change-2.30 / -0.71%
  • Shares traded682.35k
  • 1 Year change+42.47%
  • Beta0.6999
Data delayed at least 15 minutes, as of Sep 20 2024 11:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments138123569
Total Receivables, Net2,5662,5022,039
Total Inventory1,3851,3061,499
Prepaid expenses4273524
Other current assets, total242517
Total current assets4,5403,9914,149
Property, plant & equipment, net2,5672,1851,755
Goodwill, net0.060.060.06
Intangibles, net216161107
Long term investments0.570.570.59
Note receivable - long term4414382
Other long term assets591111
Total assets7,4326,4976,109
LIABILITIES
Accounts payable1,131874623
Accrued expenses464940
Notes payable/short-term debt810573537
Current portion long-term debt/capital leases161821
Other current liabilities, total182255295
Total current liabilities2,1851,7701,516
Total long term debt166179188
Total debt992771745
Deferred income tax797163
Minority interest------
Other liabilities, total908581
Total liabilities2,5202,1051,847
SHAREHOLDERS EQUITY
Common stock482482482
Additional paid-in capital2,4382,4382,438
Retained earnings (accumulated deficit)1,9651,4471,320
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total272522
Total equity4,9124,3924,262
Total liabilities & shareholders' equity7,4326,4976,109
Total common shares outstanding484848
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.